Regenxbio RGNX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $87.82M-44.0% | $170.44M+105% | $161.32M+91.3% | $155.78M+74.9% | $156.72M+80.7% | ||
| $232.55M+12.5% | $228.3M+9.5% | $219.07M+2.5% | $217.4M-0.1% | $206.77M-9.5% | ||
| $83.82M+6.5% | $82.86M+8.1% | $80.53M+6.5% | $79.7M+0.5% | $78.68M-6.5% | ||
| $344.51M+9.7% | $331.64M+4.7% | $316.25M-4.2% | $320.38M-5.2% | $314.07M-10.9% | ||
| -$256.69M-63.1% | -$161.2M+30.9% | -$154.93M+37.0% | -$164.6M+33.8% | -$157.36M+40.8% | ||
| -292.3%-192pp | -94.6%+185pp | -96%+196pp | -105.7%+174pp | -100.4%+206pp | ||
| $45.15M+134% | $45.01M+256% | $42.15M+815% | $29.8M+451% | $19.26M+217% | ||
| -$33.33M-9,908% | -$32.68M-623% | -$22.99M-432% | -$10.97M-246% | -$333K-106% | ||
| -$290.01M-83.9% | -$193.88M+14.6% | -$177.92M+25.5% | -$175.57M+27.2% | -$157.69M+39.4% | ||
| -330.2%-230pp | -113.8%+159pp | -110.3%+173pp | -112.7%+158pp | -100.6%+199pp | ||
| -$5.60-80.6% | -$3.76+18.3% | -$3.46+31.1% | -$3.43+34.8% | -$3.10+47.2% | ||
| -$241.17M-70.6% | -$145.58M+33.0% | -$139.16M+39.3% | -$148.75M+35.8% | -$141.37M+43.1% | ||
| -274.6%-184pp | -85.4%+175pp | -86.3%+186pp | -95.5%+165pp | -90.2%+196pp | ||
| -$256.69M-63.1% | -$161.2M+30.9% | -$154.93M+37.0% | -$164.6M+33.8% | -$157.36M+40.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Regenxbio's revenue?
- Regenxbio (RGNX) generated $87.8M in revenue over the trailing twelve months, down 44.0% year over year.
- Is Regenxbio profitable?
- Regenxbio is not currently profitable: it reported a net loss of $290.0M over the trailing twelve months, a -330.2% net margin.
- What are Regenxbio's profit margins?
- Gross margin is 59.7% and operating margin is -292.3%, with a -330.2% net margin.
- What is Regenxbio's earnings per share?
- Regenxbio's diluted EPS over the trailing twelve months is $-5.60.
- Where does Regenxbio's income statement data come from?
- Every line is extracted from Regenxbio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
